Dr. Robert Shepard Joins Biothera as Chief Medical Officer

EAGAN, Minn.--(Business Wire)--
Biothera has named Robert C. Shepard, M.D., F.A.C.P. as Chief Medical Officer
with responsibility for overseeing the clinical development of Imprime PGG®, the
company`s targeted immunotherapeutic drug that works synergistically with
monoclonal antibodies in the treatment of a wide range of cancers, including
colorectal and lung cancer.

"We are very pleased to welcome Dr. Shepard to the Biothera team," said Daniel
Conners, president of Biothera`s Pharmaceutical Group. "His distinguished career
in oncology and experience in clinical development make him the ideal candidate
to lead our clinical development program."

Shepard Bio

Dr. Shepard`s extensive experience includes the complete clinical development of
several drugs and immune therapies for patients with cancer. Previously he held
senior positions at several biotech and pharmaceutical companies, including
senior director and head of U.S. Oncology at i3 Oncology and medical director of
clinical research and development in oncology at AstraZeneca. Dr. Shepard also
was a medical officer at the oncology branch of CBER at the FDA where he was
involved in the review of Avastin® and Erbitux®, the monoclonal antibodies
combined with Imprime PGG in Biothera`s Phase II trials in colorectal and lung
cancer.

He has 15 years of clinical research experience at Harvard, Tufts, Hopkins, and
the University of Virginia. At UVa, Dr. Shepard was the principal investigator
(PI) for the Eastern Cooperative Oncology Group, and PI for 29 oncology clinical
trials.

Dr. Shepard is board-certified in oncology, hematology and internal medicine. He
received an A.B. in Biochemistry and Molecular Biophysics Magna cum Laude from
Harvard University and a M.D. from the Duke University School of Medicine
Medical Scientist Training Program.

Biothera Drug Development

Biothera`s clinical development program is focused on metastatic colorectal
cancer and non-small cell lung cancer. Dr. Shepard will manage all of Biothera`s
clinical initiatives including:

* A dual-arm Phase Ib/IIa trial conducted in colorectal cancer patients.
Biothera recently reported at ASCO the results of the first arm of the trial,
which combines Imprime PGG and the standard of care (Erbitux and Irinotecan®).
The second arm of the study, which is now fully enrolled, is evaluating the
effectiveness of Imprime PGG and Erbitux without chemotherapy.
* A Phase II clinical trial with metastatic colorectal cancer patients that have
a KRAS gene mutation. Launched in May 2009, the trial combines Imprime PGG and
Erbitux.
* An open-label, randomized Phase II non-small cell lung cancer trial that
combines Imprime PGG with Avastin and Carboplatin® and Paclitaxel®.
* An open-label, randomized Phase II non-small cell lung cancer trial that
combines Imprime PGG with Erbitux and Carboplatin and Paclitaxel.

Both lung cancer trials are expected to begin dosing in the next few weeks.

Other Personnel Changes

Biothera recently promoted Myra Patchen, Ph.D. to Chief Scientific Officer,
Pharmaceutical Group. Dr. Patchen has been with Biothera for several years, most
recently as executive vice president of Pharmaceutical Development. She has
extensive research experience with Imprime PGG and other yeast-derived beta
glucans.

The company also has named Quanren He, M.D., Ph.D., D.A.B.T., C.C.C.P., as
Director of Pharmacology/Toxicology. Previously, Dr. He held several positions
at CyDex Pharmaceuticals, Inc. in Lenexa, Kansas, including director of drug
safety and medical affairs. Dr. He reports to Dr. Patchen.

"We are extremely pleased with the pharmaceutical development team at Biothera,"
said Conners. "We are confident that their leadership will result in continued
success of Imprime PGG."

About Biothera, the Immune Health Company

Biothera is a biotechnology company dedicated to improving immune health. The
company is developing pharmaceuticals that target, direct and activate the
innate immune system to fight cancer. (www.biothera.com)

Biothera, the Immune Health Company
David Walsh, 651-256-4606 (direct)
VP Communications
dwalsh@biothera.com

Copyright Business Wire 2009